

## AMENDMENTS TO THE CLAIMS

### Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:

1-17. (Canceled)

~~1~~ <sup>18</sup>. (Currently amended) An isolated antibody or antibody fragment being low or not immunogenic in humans and recognizing the human 17-1A antigen as expressed on the surface of tumor cells, the antibody or antibody fragment being further characterized as comprising a human VH chain and a human VL chain wherein at least said VH chain is a VH sequence of unprimed mature human B-lymphocytes and comprises three CDRs encoded by nucleotides 91 to 105, 148 to 198 and 292 to 351 within nucleotides 1 to 381 of SEQ ID NO: 143 and said VL chain is a VL sequence of a naturally occurring human B cell repertoire and comprises three CDRs encoded by nucleotides 70 to 102, 148 to 168 and 265 to 294 within nucleotides 1 to 321 of SEQ ID NO: 141.

~~2~~ <sup>19</sup>. (Currently amended) The antibody or antibody fragment according to claim ~~18~~ <sup>1</sup>, which is an antibody ~~fragment~~.

20-30. (Canceled)

~~3~~ <sup>31</sup>. (Previously presented) The antibody or antibody fragment of claim ~~18~~ <sup>1</sup>, recognizing an epitope of the extracellular domain of the 17-1A antigen.

~~4~~ <sup>32</sup>. (Previously presented) The antibody or antibody fragment of claim ~~18~~ <sup>1</sup>, wherein said human VH chain comprises the amino acid sequence encoded by nucleotides 1 to 381 of SEQ ID NO: 143 and/or said human VL chain comprises the amino acid sequence encoded by nucleotides 1-321 of SEQ ID NO: 141.

33-37. (Canceled)

8/38

(Previously presented) A pharmaceutical composition comprising an antibody or antibody fragment according to claim ~~18, 65, 66 or 67~~<sup>1, 5, 6, 7</sup>, and a pharmaceutically acceptable carrier.

39. (Currently amended) A pharmaceutical composition comprising an antibody or antibody fragment according to claim ~~[[19]]18~~<sup>1</sup>, and a pharmaceutically acceptable carrier.

40-54. (Canceled)

9/55

(Previously presented) A pharmaceutical composition comprising an antibody or antibody fragment according to claim ~~31~~<sup>3</sup>, and a pharmaceutically acceptable carrier.

10/56

(Previously presented) A pharmaceutical composition comprising an antibody or antibody fragment according to claim ~~32~~<sup>4</sup>, and a pharmaceutically acceptable carrier.

57-64. (Canceled)

5/65

(Previously presented) The antibody or antibody fragment according to claim ~~18~~<sup>1</sup>, further comprising, fused to said human VH and VL chains, immunoglobulin constant regions of ~~heavy (CH) and light chains (CL)~~<sup>heavy (CH) and light chains (CL)</sup>, or parts thereof, or non-immunoglobulin chains, ~~respectively~~<sup>respectively</sup>.

6/66

(Previously presented) The antibody or antibody fragment according to claim ~~65~~<sup>5</sup>, wherein said constant region chains are from human IgG1 or IgG3.

7/67

(Previously presented) The antibody or antibody fragment according to claim ~~18~~<sup>1</sup>, further comprising a ~~non-proteinaceous pharmaceutical and/or other biologically active molecule~~<sup>radioisotope, chemotherapeutic agent or toxin</sup> linked to said human VH and VL chains.

68. (Canceled)